Inhibitors of Endothelin
Overview
Pharmacology
Affiliations
With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.
Li K, Wang Z, Ongachwa Machuki J, Li M, Wu Y, Niu M Front Physiol. 2022; 13:848867.
PMID: 35530510 PMC: 9075737. DOI: 10.3389/fphys.2022.848867.
Lu J, Aguilar A, Zou B, Bao W, Koldas S, Shi A Bioorg Med Chem. 2015; 23(17):5985-98.
PMID: 26190460 PMC: 4555001. DOI: 10.1016/j.bmc.2015.06.055.
Endothelin-1 and diabetic complications: focus on the vasculature.
Ergul A Pharmacol Res. 2011; 63(6):477-82.
PMID: 21292003 PMC: 7383935. DOI: 10.1016/j.phrs.2011.01.012.
Mikulic I, Petrik J, Galesic K, Romic Z, cepelak I, Zeljko-Tomic M J Clin Lab Anal. 2009; 23(6):347-56.
PMID: 19927348 PMC: 6648951. DOI: 10.1002/jcla.20324.
Piovezan A, DOrleans-Juste P, Souza G, Rae G Br J Pharmacol. 2000; 129(5):961-8.
PMID: 10696096 PMC: 1571931. DOI: 10.1038/sj.bjp.0703154.